Trial Profile
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs KW 2478 (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 05 Sep 2017 Primary endpoint (Objective clinical response rate) has not been met as per results published in the British Journal of Cancer
- 05 Sep 2017 Results published in the British Journal of Cancer
- 04 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.